Disc in Licensing Agreement with Mabwell Therapeutics for Novel Monoclonal Antibodies

 

• Disc will obtain exclusive rights to MWTX-003 and other novel anti-TMPRSS6 antibodies in the United States, Europe and other territories excluding Greater China and certain other territories in Southeast Asia
  

• MWTX-003 demonstrated potent and durable suppression of serum iron and efficacy in animal models of beta-thalassemia and polycythemia vera (PV)

• FDA has accepted the IND for MWTX-003 and Disc plans to initiate a phase 1 study of MWTX-003 in healthy volunteers during 2H’23

https://finance.yahoo.com/news/disc-medicine-announces-exclusive-licensing-120000978.html